AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in...

Related Keywords

Colorado ,United States ,United Kingdom ,Manchester ,Taiwan ,Japan ,Taiwanese ,Telisotuzumab Vedotin Teliso ,Ross Camidge ,Roopal Thakkar ,Regulatory Agency ,Facebook ,Cancer Research United Kingdom ,Exchange Commission ,Linkedin ,University Of Colorado Cancer Center ,National Cancer Institute ,Twitter ,Drug Administration ,Instagram ,Youtube ,Ministry Of Health ,Met High ,Met Intermediate ,Colorado Cancer Center ,Principal Investigator ,Breakthrough Therapy Designation ,Innovation Passport ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Overexpressing Non Small Cell Lung Cancer ,Across Clinical Trial Samples ,Real World Patient Cohorts From ,Hope National Medical ,Cancer Conference ,Non Small Cell Lung Cancer ,Agents Targeting ,Onco Targets ,Abbvie ,